ESMO 2019 featured a staggering 2,200 abstracts including 92 late breaking abstracts, befitting its standing as one of the largest oncology conferences worldwide. The Axiom Healthcare Strategies team attended the meeting, distilling 5 major trends that emerged, along with broader topics in oncology that are expected to drive the clinical and scientific discussion in coming years. Operating in a more recently 'value-focused' biopharmaceutical industry, ESMO 2019 will be remembered for practice-changing data in gynecological cancers, milestones in the PARP inhibitor class, and new frontiers in lung cancer.
ESMO 2019_White Paper
.pdf
Download PDF • 4.91MB